Boston Scientific Sees CRM Pipeline Aiding ICD Market Share Gains
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific is highlighting recent and near-term product introductions as a key component of its plan to boost market share in its cardiac rhythm management business
You may also be interested in...
New CRM launches
Boston Scientific announces CE-mark approval of the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and the Teligent ICD Jan. 22. The company says the devices, for which a full rollout in international markets is planned in the second quarter, are among the smallest and thinnest implantable defibrillators available, at 32.5 cc and 31.5 cc, respectively. Both products are pending FDA approval, with a U.S. launch expected in the second half of 2008, the firm says (1"The Gray Sheet" Oct. 29, 2007, p. 16)
New CRM launches
Boston Scientific announces CE-mark approval of the Cognis cardiac resynchronization therapy defibrillator (CRT-D) and the Teligent ICD Jan. 22. The company says the devices, for which a full rollout in international markets is planned in the second quarter, are among the smallest and thinnest implantable defibrillators available, at 32.5 cc and 31.5 cc, respectively. Both products are pending FDA approval, with a U.S. launch expected in the second half of 2008, the firm says (1"The Gray Sheet" Oct. 29, 2007, p. 16)
St. Jude Medical: Competitor’s Recall Clouds ICD Market Predictions
St. Jude Medical believes it is well positioned to continue increasing its share of the implantable cardioverter defibrillator market in 2008, even though it is too soon to predict the precise impact of competitor Medtronic's Sprint Fidelis ICD lead recall